Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Cody Chiuzan"'
Autor:
Christopher J. Valente, MD, Cody Chiuzan, PhD, Rabah Alreshq, MD, Tori Blot, Denise Fine, Stephen Helmke, Carlos Rodriguez, Natalia Sabogal, Sergio Teruya, Morgan Winburn, Damian Kurian, MD, Farbod Raiszadeh, MD, PhD, Mathew S. Maurer, MD, Frederick L. Ruberg, MD
Publikováno v:
CJC Open, Vol 5, Iss 4, Pp 292-302 (2023)
Background: Deficits of physical function are associated with poor quality of life and adverse health outcomes, but data informing the association of these assessments among Black and Hispanic outpatients with heart failure (HF) are limited. Methods:
Externí odkaz:
https://doaj.org/article/fe3ea32686644874a1337b9e5cf3faa8
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background The overwhelming majority of dose-escalation clinical trials use methods that seek a maximum tolerable dose, including rule-based methods like the 3+3, and model-based methods like CRM and EWOC. These methods assume that the incid
Externí odkaz:
https://doaj.org/article/c3f36ce90c0c4b9eb8a08d296d69e505
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Background With numerous and fast approvals of different agents including immune checkpoint inhibitors, monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established form of cancer treatment. T
Externí odkaz:
https://doaj.org/article/e251b06a5df14260a3ed5ecf4f342705
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1bc3db3a63fee6cdfca548887c81466
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
Nonparametric analytical Rank-based Enrichment Analysis (NaRnEA) is a novel gene set analysis method which leverages an analytical null model derived under the Principle of Maximum Entropy. NaRnEA critically improves over two widely used methods –
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cd1b5313d58886ed828b3bb1d913103
https://doi.org/10.1101/2021.10.02.462873
https://doi.org/10.1101/2021.10.02.462873
Autor:
Christopher Valente, Cody Chiuzan, Rabah Alreshq, Tori Blot, Denise Fine, Stephen Helmke, Carlos Rodriguez, Natalia Sabogal, Sergio Teruya, Morgan Winburn, Mathew Maurer, Frederick L. Ruberg
Publikováno v:
Journal of Cardiac Failure. 28:S34-S35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08ce6b0db6a6a1580ca9315ba93d30d0
https://doi.org/10.1016/j.cardfail.2022.03.093
https://doi.org/10.1016/j.cardfail.2022.03.093
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
BMC Cancer
BMC Cancer
Background The overwhelming majority of dose-escalation clinical trials use methods that seek a maximum tolerable dose, including rule-based methods like the 3+3, and model-based methods like CRM and EWOC. These methods assume that the incidences of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa9190f07fbda0d8c525f8ad7e35802c
https://doi.org/10.1186/s12885-021-08440-0
https://doi.org/10.1186/s12885-021-08440-0
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f440092b90d67f34cbca89e882bc5e
https://doi.org/10.1158/1538-7445.am2021-645
https://doi.org/10.1158/1538-7445.am2021-645
Publikováno v:
Cancer Research. 80:CT107-CT107
Background: Despite the anticancer activity of Pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors to target individual HDACs is emerging as a novel and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c86a8b50ef78b42941d8eee23b7e7a5b
https://doi.org/10.1158/1538-7445.am2020-ct107
https://doi.org/10.1158/1538-7445.am2020-ct107
Autor:
Robert N. Taub, Gleneara E. Bates, Allison M. Greene, Joshua Leinwand, Michael D. Kluger, Cody Chiuzan, Danielle R. Heller, John A. Chabot
Publikováno v:
Annals of Surgical Oncology. 24:3818-3824
The prognosis for patients with diffuse malignant peritoneal mesothelioma has dramatically improved with cytoreductive surgery and intraperitoneal chemotherapy. Little is known about disease recurrence after treatment. We analyzed the time to and pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2fca6b66f378e5fc9cf8582bd8bd83e
https://doi.org/10.1245/s10434-017-6106-x
https://doi.org/10.1245/s10434-017-6106-x